Who is eligible for clinical trial NCT07415954?

Participants must meet the protocol's inclusion criteria for Diabetes Mellitus, Type 2. The stated age range is 18 Years to 75 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT07415954 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-07

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes (NCT07415954)

Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Novo Nordisk A/S

🩺 Plain-English Summary (8th-Grade Level)

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (4 items).

Location: First Valley Medical Group — Lancaster, California

Age range: 18 Years to 75 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Male or female (sex at birth).
Age 18-75 years (both inclusive) at the time of signing the informed consent.
Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening.
Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline).

Usually NOT eligible if any of the following apply:

Exclusion criteria
Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (63 Sites)

Showing the first 25 of 63 sites.

First Valley Medical Group — Lancaster, California
Torrance Clinical Research Institute, Inc. — Lomita, California
Ark Clinical Research — Long Beach, California
Pacific Clinical Studies — Los Alamitos, California
Wetlin Research Associates, Inc. — San Diego, California
Diablo Clinical Research, Inc. — Walnut Creek, California
Encore Medical Research LLC — Hollywood, Florida
Bioclinical Research Alliance — Miami, Florida
South Broward Research LLC — Miramar, Florida
West Orange Endocrinology — Ocoee, Florida
Encore Medical Research of Weston — Weston, Florida
Elite Clinical Trials — Blackfoot, Idaho
Cedar-Crosse Research Center — Chicago, Illinois
Brigham & Women's Hospital — Boston, Massachusetts
Headlands Research — Springfield, Missouri
PharmQuest — Greensboro, North Carolina
Piedmont Healthcare Statesville — Statesville, North Carolina
Providence Center for Clinical Research — Dayton, Ohio
CNS Healthcare — Memphis, Tennessee
University of Texas Southwestern Medical Center — Dallas, Texas
JCCT- Juno NW Houston — Houston, Texas
Consano Clinical Research, LLC — Shavano Park, Texas
Frontier Clinical Research - Kingwood — Kingwood, West Virginia
Opca bolnica Karlovac — Karlovac,
Poliklinika SLAVONIJA OSIJEK — Osijek,

📞 Contact the Study Coordinator

Phone: (866) 867-7178

Email: clinicaltrials@novonordisk.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Diabetes Mellitus, Type 2

Phenotypic and Genotypic Characterization of Patients With Dysmetabolism in Greenland — Nuuk, Sermersooq
Project Dulce for Arab Americans With Type 2 Diabetes — El Cajon, California
Sleep for Health Study on the Effects of Cognitive Behavioral Therapy for Insomnia on Diabetes Risk — Portland, Oregon
Integrating Abbott Point-of-Care Technologies and the Community Scientist Model to Support HbA1c Testing Per ADA — Santa Barbara, California
Diabetes Discharge Transitional CGM Study (DDT-CGM) — Logan, Utah

Explore by condition: All Diabetes Mellitus, Type 2 clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗